Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation
- 10 July 2009
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (20) , 3398-3409
- https://doi.org/10.1200/jco.2008.20.1178
Abstract
Patients with hematologic malignancy and hematopoietic cell transplant (HCT) recipients are at increased risk for invasive fungal infection (IFI) as a result of immunosuppression or organ damage stemming from their underlying disease, its treatment, or both. Such IFIs can cause significant morbidity and mortality, and the diagnosis and treatment of infected patients frequently are clinically challenging. This article discusses the epidemiology and risk factors for IFI in patients with hematologic malignancy and HCT recipients. The pros and cons of available antifungal agents are discussed, and evolving treatment strategies and recent prophylaxis guidelines from various professional organizations are reviewed. Finally, recommendations are offered for antifungal prophylaxis according to risk group.Keywords
This publication has 129 references indexed in Scilit:
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Prophylaxis and Aspergillosis — Has the Principle Been Proven?New England Journal of Medicine, 2007
- Antifungal Susceptibilities of the Species of the Pseudallescheria boydii ComplexAntimicrobial Agents and Chemotherapy, 2006
- In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and YeastsAntimicrobial Agents and Chemotherapy, 2006
- International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemiaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Increased frequency of non-fumigatus Aspergillus species in amphotericin B– or triazole–pre-exposed cancer patients with positive cultures for aspergilliDiagnostic Microbiology and Infectious Disease, 2005
- Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 2004
- A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile NeutropeniaClinical Infectious Diseases, 2000
- A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow TransplantationNew England Journal of Medicine, 1992